- Home
- LSTA vs IGC Comparison
LSTA vs IGC Comparison
Compare LSTA & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- IGC
- Stock Information
- Founded
- LSTA 1980
- IGC 2005
- Country
- LSTA United States
- IGC United States
- Employees
- LSTA N/A
- IGC N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- IGC Health Care
- Exchange
- LSTA Nasdaq
- IGC Nasdaq
- Market Cap
- LSTA 20.0M
- IGC 18.0M
- IPO Year
- LSTA N/A
- IGC N/A
- Fundamental
- Price
- LSTA $2.39
- IGC $0.29
- Analyst Decision
- LSTA Strong Buy
- IGC Strong Buy
- Analyst Count
- LSTA 1
- IGC 2
- Target Price
- LSTA $15.00
- IGC $3.88
- AVG Volume (30 Days)
- LSTA 13.3K
- IGC 231.3K
- Earning Date
- LSTA 05-08-2025
- IGC 02-18-2025
- Dividend Yield
- LSTA N/A
- IGC N/A
- EPS Growth
- LSTA N/A
- IGC N/A
- EPS
- LSTA N/A
- IGC N/A
- Revenue
- LSTA $1,000,000.00
- IGC $1,236,000.00
- Revenue This Year
- LSTA N/A
- IGC N/A
- Revenue Next Year
- LSTA N/A
- IGC $18.34
- P/E Ratio
- LSTA N/A
- IGC N/A
- Revenue Growth
- LSTA N/A
- IGC 1.65
- 52 Week Low
- LSTA $1.87
- IGC $0.25
- 52 Week High
- LSTA $4.20
- IGC $0.63
- Technical
- Relative Strength Index (RSI)
- LSTA 60.67
- IGC 51.68
- Support Level
- LSTA $1.91
- IGC $0.27
- Resistance Level
- LSTA $2.09
- IGC $0.30
- Average True Range (ATR)
- LSTA 0.18
- IGC 0.02
- MACD
- LSTA 0.06
- IGC 0.00
- Stochastic Oscillator
- LSTA 100.00
- IGC 88.00
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.